Medical and Societal information from the Research Community
Number of Articles: 17,750,454 Number of Contributors: 57 Number of Queries: 12,901,611
Save this page: Save to http://del.icio.us Save to http://www.reddit.com Save to http://www.digg.com Save to Google Bookmarks Save to Yahoo! My Web  Send this page

  Login  or Create a Free Account
Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam.
Felice Nava,Stefania Premi,Ezio Manzato,Wally Campagnola,Alfio Lucchini,Gian Luigi Gessa
 
In 42 alcoholic inpatients we performed an open randomized study to compare the effects of diazepam and gamma-hydroxybutyrate (GHB) on the suppression of severe alcohol withdrawal syndrome and hypercortisolism. Both diazepam (.5 mg/kg bodyweight, q.i.d.) and GHB (50 mg/kg bodyweight, q.i.d.) were orally administered for three weeks. During all study period, GHB was more able than diazepam in reducing both withdrawal syndrome and hypercortisolism. These effects were evident during the first week of treatment and persisted throughout the study period. The results confirm a strict correlation between high levels of plasma cortisol and alcohol withdrawal symptoms and they show a slight superiority of GHB over diazepam in the suppression of both ethanol withdrawal and hypercortisolism. Taken together, our data suggest that GHB may act as potent anti-withdrawal agent in severe abstinent alcoholics.

KEYWORDS:
      
 ESRNexus is provided as a service by TrialStat Corporation. ESRNexus is a registered trademark of TrialStat Corporation. Copyright 2008. View a list of all articles here